Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19

23Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVES: The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19. METHODS: Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events. RESULTS: The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group. CONCLUSION: Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted.

References Powered by Scopus

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

19977Citations
N/AReaders
Get full text

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

8787Citations
N/AReaders
Get full text

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

6720Citations
N/AReaders
Get full text

Cited by Powered by Scopus

MSCs vs. iPSCs: Potential in therapeutic applications

44Citations
N/AReaders
Get full text

Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects

41Citations
N/AReaders
Get full text

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial

39Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wei, F., Kong, D., Li, T., Li, A., Tan, Y., Fang, J., … Zheng, C. (2021). Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19. Clinics, 76. https://doi.org/10.6061/CLINICS/2021/E2604

Readers over time

‘21‘22‘23‘24‘2509182736

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

67%

Researcher 4

17%

Professor / Associate Prof. 3

13%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

57%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Biochemistry, Genetics and Molecular Bi... 3

14%

Immunology and Microbiology 3

14%

Save time finding and organizing research with Mendeley

Sign up for free
0